An analysis of recent filings from American politicians shows that Accenture (NYSE: ACN) and Boston Scientific (NYSE: BSX) saw an uptick in purchases from notable politicians. Rep. Gilbert Ray Cisneros, Jr. (D-CA) bought Boston Scientific shares, according to a filing earlier this month. The trade was made on August 18, 2026. Rep. Ro Khanna (D-CA) also bought the stock twice, on August 3 and August 10, 2026, according to a filing filed on September 4, 2026. Neither politician sold Boston Scientific shares in the same period. Cisneros and Khanna were also the two buyers of Accenture shares in July and August.
This is based on data from Quiver Quantitative, a platform that tracks congressional stock trades from politicians.
Let’s focus on BSX in this article.
Bull Case: Cyberattack a Temporary Setback
BSX is down about 50% so far this year amid a cyberattack that disrupted manufacturing, order processing and shipments, forcing the company to withdraw its previous third-quarter and full-year outlook. Bulls say the market has priced in too severe an outcome. By Sept. 8, the company said its major distribution centers were shipping at or above normal levels, sterilization facilities were operating, and manufacturing had restarted at most plants. Bulls believe much of the disrupted revenue could be delayed rather than permanently lost as hospitals wait for products, reschedule procedures and the company works through its backlog.
Bulls also point to a business that was still growing. Second-quarter revenue rose 7.5% year over year and organic growth was 7%. Several core franchises delivered double-digit organic growth, including Interventional Cardiology and Vascular Therapies, Interventional Oncology and Embolization, and Neuromodulation.
Bear Case
Bears say Boston Scientific’s business was already showing signs of a slowdown before the cyberattack. Sales growth slowed sharply for WATCHMAN, a heart implant that lowers stroke risk in people with an irregular heartbeat, and for its heart-rhythm treatment business in the US, where competitors are taking market share. Bears also worry that the company could lose some customers to rivals after the attack, while its large Penumbra acquisition adds debt and will weigh on earnings in the first year.
Valuation
The stock trades at 13.07 times forward non-GAAP earnings, about 30.64% below the healthcare-sector median of 18.85 times. Its trailing non-GAAP P/E of 13.39 times is 26.61% below the sector median. Bulls say the market is valuing BSX as a damaged business despite continued growth, strong margins and substantial cash generation.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.